Shire's Full Year 2018 Results

– 2018 product sales growth +3.9% and $4.6 billion operating cash flow
– Solid growth contributions in 2018 from Immunology, recently-launched products, international markets, and Neuroscience
– Advanced innovative pipeline including FDA approvals of TAKHZYRO and MOTEGRITY

OSAKA, JAPAN, February 15, 2019 – On January 8, 2019, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Headquarters: Chuo-ku, Osaka, “Takeda”) acquired Shire plc ("Shire"). Today, Takeda announced Shire’s results for the year ended December 31, 2018, the last full year prior to the acquisition. These results reflect Shire’s disclosure method and does not preclude how Takeda will neither describe its business and report its results moving forward.

Please see the release for the details.